000263988 001__ 263988
000263988 005__ 20240612120606.0
000263988 0247_ $$2doi$$a10.1002/mds.29497
000263988 0247_ $$2pmid$$apmid:37449706
000263988 0247_ $$2ISSN$$a0885-3185
000263988 0247_ $$2ISSN$$a1531-8257
000263988 0247_ $$2altmetric$$aaltmetric:151560252
000263988 037__ $$aDZNE-2023-00922
000263988 041__ $$aEnglish
000263988 082__ $$a610
000263988 1001_ $$00000-0002-7892-8621$$aXylaki, Mary$$b0
000263988 245__ $$aExtracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
000263988 260__ $$aNew York, NY$$bWiley$$c2023
000263988 3367_ $$2DRIVER$$aarticle
000263988 3367_ $$2DataCite$$aOutput Types/Journal article
000263988 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718180239_28347$$xReview Article
000263988 3367_ $$2BibTeX$$aARTICLE
000263988 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000263988 3367_ $$00$$2EndNote$$aJournal Article
000263988 520__ $$aParkinson's disease (PD) biomarkers are needed by both clinicians and researchers (for diagnosis, identifying study populations, and monitoring therapeutic response). Imaging, genetic, and biochemical biomarkers have been widely studied. In recent years, extracellular vesicles (EVs) have become a promising material for biomarker development. Proteins and molecular material from any organ, including the central nervous system, can be packed into EVs and transported to the periphery into easily obtainable biological specimens like blood, urine, and saliva. We performed a systematic review and meta-analysis of articles (published before November 15, 2022) reporting biomarker assessment in EVs in PD patients and healthy controls (HCs). Biomarkers were analyzed using random effects meta-analysis and the calculated standardized mean difference (Std.MD). Several proteins and ribonucleic acids have been identified in EVs in PD patients, but only α-synuclein (aSyn) and leucine-rich repeat kinase 2 (LRRK2) were reported in sufficient studies (n = 24 and 6, respectively) to perform a meta-analysis. EV aSyn was significantly increased in neuronal L1 cell adhesion molecule (L1CAM)-positive blood EVs in PD patients compared to HCs (Std.MD = 1.84, 95% confidence interval = 0.76-2.93, P = 0.0009). Further analysis of the biological sample and EV isolation method indicated that L1CAM-IP (immunoprecipitation) directly from plasma was the best isolation method for assessing aSyn in PD patients. Upcoming neuroprotective clinical trials immediately need peripheral biomarkers for identifying individuals at risk of developing PD. Overall, the improved sensitivity of assays means they can identify biomarkers in blood that reflect changes in the brain. CNS-derived EVs in blood will likely play a major role in biomarker development in the coming years. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000263988 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000263988 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000263988 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000263988 650_7 $$2Other$$aα-synuclein
000263988 650_7 $$2Other$$aα-synuclein
000263988 650_7 $$2Other$$aL1 cell adhesion molecule
000263988 650_7 $$2Other$$aParkinson's disease
000263988 650_7 $$2Other$$abiomarker
000263988 650_7 $$2Other$$aexosomes
000263988 650_7 $$2Other$$aplasma
000263988 650_7 $$2Other$$aα-synuclein
000263988 650_7 $$2NLM Chemicals$$aNeural Cell Adhesion Molecule L1
000263988 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000263988 650_7 $$2NLM Chemicals$$aBiomarkers
000263988 650_2 $$2MeSH$$aHumans
000263988 650_2 $$2MeSH$$aParkinson Disease: metabolism
000263988 650_2 $$2MeSH$$aNeural Cell Adhesion Molecule L1: metabolism
000263988 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000263988 650_2 $$2MeSH$$aExtracellular Vesicles: metabolism
000263988 650_2 $$2MeSH$$aBiomarkers
000263988 650_2 $$2MeSH$$aSexually Transmitted Diseases: metabolism
000263988 7001_ $$aChopra, Avika$$b1
000263988 7001_ $$00000-0001-5713-2141$$aWeber, Sandrina$$b2
000263988 7001_ $$00000-0002-7752-2443$$aBartl, Michael$$b3
000263988 7001_ $$0P:(DE-2719)2814138$$aOuteiro, Tiago F$$b4$$udzne
000263988 7001_ $$0P:(DE-2719)9001340$$aMollenhauer, Brit$$b5$$eLast author$$udzne
000263988 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.29497$$gVol. 38, no. 9, p. 1585 - 1597$$n9$$p1585 - 1597$$tMovement disorders$$v38$$x0885-3185$$y2023
000263988 8564_ $$uhttps://pub.dzne.de/record/263988/files/DZNE-2023-00922.pdf$$yOpenAccess
000263988 8564_ $$uhttps://pub.dzne.de/record/263988/files/DZNE-2023-00922.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000263988 909CO $$ooai:pub.dzne.de:263988$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000263988 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000263988 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001340$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000263988 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000263988 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000263988 9141_ $$y2023
000263988 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000263988 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000263988 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-11$$wger
000263988 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000263988 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000263988 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000263988 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000263988 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2023-10-24
000263988 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000263988 980__ $$ajournal
000263988 980__ $$aVDB
000263988 980__ $$aI:(DE-2719)1410002
000263988 980__ $$aUNRESTRICTED
000263988 9801_ $$aFullTexts